Hospital Infection Therapeutics Market- Global Industry Analysis and forecast(2023-2029)


 Hospital Infection Therapeutics Market size is expected to reach nearly US$ 57.71 Bn. by 2029 with the CAGR of 20.3% during the forecast period.

Hospital Infection Therapeutics Market Drivers and Restrains:

Hospital-acquired infections are highly dominant adverse events in the health care industry and one of the leading cause of death across the world. Lack of knowledge about the blood transfusion safety measures, understaffing, insufficient hospital equipment and poor infrastructure particularly seen in the emerging and underdeveloped nations are some of the factors responsible for increasing hospital infection, which in turn increases the hospital infection therapeutics market.Hospital Infection Therapeutics MarketTo know about the Research Methodology:-Request Free Sample Report

The hospital infection therapeutics market is driven by factors like an increase in the geriatric population, significant patient population in developing countries demanding proper treatment, and investments by public and private companies for R&D on anti-infective drugs against resistant bacteria. According to the Centers for Disease Control and Prevention (CDC), X out of every xx hospital admitted patient gets contracted with HAIs. Moreover, in the U.S., around xx hospitalized patients died from hospital-acquired infections.

However, a surge in the incidence of treatment-emergent resistance, significant investment required due to high attrition rate in clinical trials, and changing reimbursement policies are resulting in limited pipeline drugs are hampering the market growth at the global level. Investment in R&D on non-antibiotic treatment options and partnerships for co-development and commercialization of anti-infective agents are likely to create lucrative opportunities in the hospital infection therapeutics market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Segment Analysis:

Based on drugs type, the hospital infection therapeutics market has been segmented into Antibiotics Drugs, Antifungal Drugs, and Antiviral Drugs. The antibacterial drugs segment accounted for dominant market share in 2022, owing to an increase in initiatives such as the global action plan on antimicrobial resistance by WHO and Drive AB by Innovative Medicines Initiative, and the presence of key companies involved in the manufacture of anti-bacterial drugs. The relatively stable growth rate of the segment is credited to the rise in antibiotic resistance of bacteria and limited pipeline drug candidates. The anti-viral drugs segment is expected to grow at the largest CAGR of xx% during the forecast period, owing to a rise in the prevalence of severe bloodstream infections and rise in focus on research and development to reduce the risk of virus structural mutations.

Based on application, the hospital infection therapeutics market has been segmented into Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders, and Other Hospital Infections. The pneumonia segment hold dominate the market share during the forecast period with significant growth rate, followed by surgical site infections, due to increase in incidence rate of respiratory infections among the aged population, comparatively above-average cost of treatment, and incidence of multidrug-resistant micro-organisms in ICU units.

Regional Insights:

Geographically, the hospital infection therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the hospital infection therapeutics market in 2022, due to improved healthcare awareness, high ratio of hospitals as compared to population of the region, increasing count of multidrug-resistant microbial pathogens and increase in aging population of the region. The market in Asia Pacific is expected to expand at a high CAGR of xx% during the forecast period, owing to increased incidences of hospital infections and high demands of therapeutic drugs in emerging countries such as India and China. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are expected to impelling the market growth in this region over the forecast period.

Competitive landscape

Major Key players operating in this market are Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Bayer AG, and Sanofi S.A. Manufacturers in the hospital infection therapeutics are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Hospital Infection Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Hospital Infection Therapeutics Market dynamics, structure by analyzing the market segments and project the Hospital Infection Therapeutics Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Hospital Infection Therapeutics Market make the report investor’s guide.

Hospital Infection Therapeutics Market Scope: Inquire before buying






Global Hospital Infection Therapeutics Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 15.82 Bn.




Forecast Period 2023 to 2029 CAGR:
20.3%
Market Size in 2029:
US $ 57.71 Bn.




 Segments Covered:
by Drugs Type
Antibiotics Drugs
Antifungal Drugs
Antiviral Drugs




by Application
Bloodstream Infections
Pneumonia
Surgical Site Infections
Urinary Tract Infections
Gastrointestinal Disorders
Other Hospital Infections






by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Hospital Infection Therapeutics Market, Key Players:

1. Merck & Co., Inc.
2. Pfizer, Inc.
3. GlaxoSmithKline plc
4. AstraZeneca
5. Johnson & Johnson Services, Inc.
6. F. Hoffmann-La Roche Ltd.
7. Bayer AG
8. Allergan plc
9. Sanofi S.A.
10.Gilead Sciences, Inc.
11.Basilea Pharmaceutica Ltd.
12.Bristol-Myers Squibb Company
13.Actavis plc
14.Cubist Pharmaceuticals, Inc.
15.Spero Therapeutics
16.BioSpace, Inc.
17.POLYPID
18.Novartis AG
19.AbbVie Inc.
20.Bellerophon Therapeutics.

Frequently Asked Questions:

1. Which region has the largest share in Global Hospital Infection Therapeutics Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Hospital Infection Therapeutics Market?
Ans: The global market is growing at a CAGR of 20.3% during forecasting period 2023-2029.

3. What is scope of the Global Hospital Infection Therapeutics market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Hospital Infection Therapeutics market?
Ans: The important key players in the global market are – Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Gilead Sciences, Inc., Basilea Pharmaceutica Ltd., Bristol-Myers Squibb Company, Actavis plc, Cubist Pharmaceuticals, Inc., Spero Therapeutics, BioSpace, Inc., POLYPID, and Novartis AG

5. What is the study period of this market?
Ans: The Global Hospital Infection Therapeutics Market is studied from 2022 to 2029. 




Hospital Infection Therapeutics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Hospital Infection Therapeutics Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global Hospital Infection Therapeutics Market Analysis and Forecast
6.1. Global Hospital Infection Therapeutics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Drugs Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type
7.4. Global Hospital Infection Therapeutics Market Size (US$ Bn) Forecast, by Drugs Type
7.5. Global Hospital Infection Therapeutics Market Analysis, by Drugs Type
7.6. Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Drugs Type

8. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Hospital Infection Therapeutics Market Value Share Analysis, by Application
8.4. Global Hospital Infection Therapeutics Market Size (US$ Bn) Forecast, by Application
8.5. Global Hospital Infection Therapeutics Market Analysis, by Application
8.6. Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Application

9. Global Hospital Infection Therapeutics Market Analysis, by Region
9.1. Global Hospital Infection Therapeutics Market Value Share Analysis, by Region
9.2. Global Hospital Infection Therapeutics Market Size (US$ Bn) Forecast, by Region
9.3. Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Region

10. North America Hospital Infection Therapeutics Market Analysis
10.1. Key Findings
10.2. North America Hospital Infection Therapeutics Market Overview
10.3. North America Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type
10.4. North America Hospital Infection Therapeutics Market Forecast, by Drugs Type
10.4.1. Antibiotics Drugs
10.4.2. Antifungal Drugs
10.4.3. Antiviral Drugs
10.5. North America Hospital Infection Therapeutics Market Value Share Analysis, by Application
10.6. North America Hospital Infection Therapeutics Market Forecast, by Application
10.6.1. Bloodstream Infections
10.6.2. Pneumonia
10.6.3. Surgical Site Infections
10.6.4. Urinary Tract Infections
10.6.5. Gastrointestinal Disorders
10.6.6. Other Hospital Infections
10.7. North America Hospital Infection Therapeutics Market Value Share Analysis, by Country
10.8. North America Hospital Infection Therapeutics Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Hospital Infection Therapeutics Market Analysis, by Country
10.10. U.S. Hospital Infection Therapeutics Market Forecast, by Drugs Type
10.10.1. Antibiotics Drugs
10.10.2. Antifungal Drugs
10.10.3. Antiviral Drugs
10.11. U.S. Hospital Infection Therapeutics Market Forecast, by Application
10.11.1. Bloodstream Infections
10.11.2. Pneumonia
10.11.3. Surgical Site Infections
10.11.4. Urinary Tract Infections
10.11.5. Gastrointestinal Disorders
10.11.6. Other Hospital Infections
10.12. Canada Hospital Infection Therapeutics Market Forecast, by Drugs Type
10.12.1. Antibiotics Drugs
10.12.2. Antifungal Drugs
10.12.3. Antiviral Drugs
10.13. Canada Hospital Infection Therapeutics Market Forecast, by Application
10.13.1. Bloodstream Infections
10.13.2. Pneumonia
10.13.3. Surgical Site Infections
10.13.4. Urinary Tract Infections
10.13.5. Gastrointestinal Disorders
10.13.6. Other Hospital Infections
10.14. North America Hospital Infection Therapeutics Market Attractiveness Analysis
10.14.1. By Drugs Type
10.14.2. By Application
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Hospital Infection Therapeutics Market Analysis
11.1. Key Findings
11.2. Europe Hospital Infection Therapeutics Market Overview
11.3. Europe Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type
11.4. Europe Hospital Infection Therapeutics Market Forecast, by Drugs Type
11.4.1. Antibiotics Drugs
11.4.2. Antifungal Drugs
11.4.3. Antiviral Drugs
11.5. Europe Hospital Infection Therapeutics Market Value Share Analysis, by Application
11.6. Europe Hospital Infection Therapeutics Market Forecast, by Application
11.6.1. Bloodstream Infections
11.6.2. Pneumonia
11.6.3. Surgical Site Infections
11.6.4. Urinary Tract Infections
11.6.5. Gastrointestinal Disorders
11.6.6. Other Hospital Infections
11.7. Europe Hospital Infection Therapeutics Market Value Share Analysis, by Country
11.8. Europe Hospital Infection Therapeutics Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Hospital Infection Therapeutics Market Analysis, by Country
11.10. Germany Hospital Infection Therapeutics Market Forecast, by Drugs Type
11.10.1. Antibiotics Drugs
11.10.2. Antifungal Drugs
11.10.3. Antiviral Drugs
11.11. Germany Hospital Infection Therapeutics Market Forecast, by Application
11.11.1. Bloodstream Infections
11.11.2. Pneumonia
11.11.3. Surgical Site Infections
11.11.4. Urinary Tract Infections
11.11.5. Gastrointestinal Disorders
11.11.6. Other Hospital Infections
11.12. U.K. Hospital Infection Therapeutics Market Forecast, by Drugs Type
11.12.1. Antibiotics Drugs
11.12.2. Antifungal Drugs
11.12.3. Antiviral Drugs
11.13. U.K. Hospital Infection Therapeutics Market Forecast, by Application
11.13.1. Bloodstream Infections
11.13.2. Pneumonia
11.13.3. Surgical Site Infections
11.13.4. Urinary Tract Infections
11.13.5. Gastrointestinal Disorders
11.13.6. Other Hospital Infections
11.14. France Hospital Infection Therapeutics Market Forecast, by Drugs Type
11.14.1. Antibiotics Drugs
11.14.2. Antifungal Drugs
11.14.3. Antiviral Drugs
11.15. France Hospital Infection Therapeutics Market Forecast, by Application
11.15.1. Bloodstream Infections
11.15.2. Pneumonia
11.15.3. Surgical Site Infections
11.15.4. Urinary Tract Infections
11.15.5. Gastrointestinal Disorders
11.15.6. Other Hospital Infections
11.16. Italy Hospital Infection Therapeutics Market Forecast, by Drugs Type
11.16.1. Antibiotics Drugs
11.16.2. Antifungal Drugs
11.16.3. Antiviral Drugs
11.17. Italy Hospital Infection Therapeutics Market Forecast, by Application
11.17.1. Bloodstream Infections
11.17.2. Pneumonia
11.17.3. Surgical Site Infections
11.17.4. Urinary Tract Infections
11.17.5. Gastrointestinal Disorders
11.17.6. Other Hospital Infections
11.18. Spain Hospital Infection Therapeutics Market Forecast, by Drugs Type
11.18.1. Antibiotics Drugs
11.18.2. Antifungal Drugs
11.18.3. Antiviral Drugs
11.19. Spain Hospital Infection Therapeutics Market Forecast, by Application
11.19.1. Bloodstream Infections
11.19.2. Pneumonia
11.19.3. Surgical Site Infections
11.19.4. Urinary Tract Infections
11.19.5. Gastrointestinal Disorders
11.19.6. Other Hospital Infections
11.20. Rest of Europe Hospital Infection Therapeutics Market Forecast, by Drugs Type
11.20.1. Antibiotics Drugs
11.20.2. Antifungal Drugs
11.20.3. Antiviral Drugs
11.21. Rest of Europe Hospital Infection Therapeutics Market Forecast, by Application
11.21.1. Bloodstream Infections
11.21.2. Pneumonia
11.21.3. Surgical Site Infections
11.21.4. Urinary Tract Infections
11.21.5. Gastrointestinal Disorders
11.21.6. Other Hospital Infections
11.22. Europe Hospital Infection Therapeutics Market Attractiveness Analysis
11.22.1. By Drugs Type
11.22.2. By Application
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific Hospital Infection Therapeutics Market Analysis
12.1. Key Findings
12.2. Asia Pacific Hospital Infection Therapeutics Market Overview
12.3. Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type
12.4. Asia Pacific Hospital Infection Therapeutics Market Forecast, by Drugs Type
12.4.1. Antibiotics Drugs
12.4.2. Antifungal Drugs
12.4.3. Antiviral Drugs
12.5. Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Application
12.6. Asia Pacific Hospital Infection Therapeutics Market Forecast, by Application
12.6.1. Bloodstream Infections
12.6.2. Pneumonia
12.6.3. Surgical Site Infections
12.6.4. Urinary Tract Infections
12.6.5. Gastrointestinal Disorders
12.6.6. Other Hospital Infections
12.7. Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Country
12.8. Asia Pacific Hospital Infection Therapeutics Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Hospital Infection Therapeutics Market Analysis, by Country
12.10. China Hospital Infection Therapeutics Market Forecast, by Drugs Type
12.10.1. Antibiotics Drugs
12.10.2. Antifungal Drugs
12.10.3. Antiviral Drugs
12.11. China Hospital Infection Therapeutics Market Forecast, by Application
12.11.1. Bloodstream Infections
12.11.2. Pneumonia
12.11.3. Surgical Site Infections
12.11.4. Urinary Tract Infections
12.11.5. Gastrointestinal Disorders
12.11.6. Other Hospital Infections
12.12. India Hospital Infection Therapeutics Market Forecast, by Drugs Type
12.12.1. Antibiotics Drugs
12.12.2. Antifungal Drugs
12.12.3. Antiviral Drugs
12.13. India Hospital Infection Therapeutics Market Forecast, by Application
12.13.1. Bloodstream Infections
12.13.2. Pneumonia
12.13.3. Surgical Site Infections
12.13.4. Urinary Tract Infections
12.13.5. Gastrointestinal Disorders
12.13.6. Other Hospital Infections
12.14. Japan Hospital Infection Therapeutics Market Forecast, by Drugs Type
12.14.1. Antibiotics Drugs
12.14.2. Antifungal Drugs
12.14.3. Antiviral Drugs
12.15. Japan Hospital Infection Therapeutics Market Forecast, by Application
12.15.1. Bloodstream Infections
12.15.2. Pneumonia
12.15.3. Surgical Site Infections
12.15.4. Urinary Tract Infections
12.15.5. Gastrointestinal Disorders
12.15.6. Other Hospital Infections
12.16. ASEAN Hospital Infection Therapeutics Market Forecast, by Drugs Type
12.16.1. Antibiotics Drugs
12.16.2. Antifungal Drugs
12.16.3. Antiviral Drugs
12.17. ASEAN Hospital Infection Therapeutics Market Forecast, by Application
12.17.1. Bloodstream Infections
12.17.2. Pneumonia
12.17.3. Surgical Site Infections
12.17.4. Urinary Tract Infections
12.17.5. Gastrointestinal Disorders
12.17.6. Other Hospital Infections
12.18. Rest of Asia Pacific Hospital Infection Therapeutics Market Forecast, by Drugs Type
12.18.1. Antibiotics Drugs
12.18.2. Antifungal Drugs
12.18.3. Antiviral Drugs
12.19. Rest of Asia Pacific Hospital Infection Therapeutics Market Forecast, by Application
12.19.1. Bloodstream Infections
12.19.2. Pneumonia
12.19.3. Surgical Site Infections
12.19.4. Urinary Tract Infections
12.19.5. Gastrointestinal Disorders
12.19.6. Other Hospital Infections
12.20. Asia Pacific Hospital Infection Therapeutics Market Attractiveness Analysis
12.20.1. By Drugs Type
12.20.2. By Application
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa Hospital Infection Therapeutics Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Hospital Infection Therapeutics Market Overview
13.3. Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type
13.4. Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Drugs Type
13.4.1. Antibiotics Drugs
13.4.2. Antifungal Drugs
13.4.3. Antiviral Drugs
13.5. Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Application
13.6. Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Application
13.6.1. Bloodstream Infections
13.6.2. Pneumonia
13.6.3. Surgical Site Infections
13.6.4. Urinary Tract Infections
13.6.5. Gastrointestinal Disorders
13.6.6. Other Hospital Infections
13.7. Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Country
13.8. Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Hospital Infection Therapeutics Market Analysis, by Country
13.10. GCC Hospital Infection Therapeutics Market Forecast, by Drugs Type
13.10.1. Antibiotics Drugs
13.10.2. Antifungal Drugs
13.10.3. Antiviral Drugs
13.11. GCC Hospital Infection Therapeutics Market Forecast, by Application
13.11.1. Bloodstream Infections
13.11.2. Pneumonia
13.11.3. Surgical Site Infections
13.11.4. Urinary Tract Infections
13.11.5. Gastrointestinal Disorders
13.11.6. Other Hospital Infections
13.12. South Africa Hospital Infection Therapeutics Market Forecast, by Drugs Type
13.12.1. Antibiotics Drugs
13.12.2. Antifungal Drugs
13.12.3. Antiviral Drugs
13.13. South Africa Hospital Infection Therapeutics Market Forecast, by Application
13.13.1. Bloodstream Infections
13.13.2. Pneumonia
13.13.3. Surgical Site Infections
13.13.4. Urinary Tract Infections
13.13.5. Gastrointestinal Disorders
13.13.6. Other Hospital Infections
13.14. Rest of Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Drugs Type
13.14.1. Antibiotics Drugs
13.14.2. Antifungal Drugs
13.14.3. Antiviral Drugs
13.15. Rest of Middle East & Africa Hospital Infection Therapeutics Market Forecast, by Application
13.15.1. Bloodstream Infections
13.15.2. Pneumonia
13.15.3. Surgical Site Infections
13.15.4. Urinary Tract Infections
13.15.5. Gastrointestinal Disorders
13.15.6. Other Hospital Infections
13.16. Middle East & Africa Hospital Infection Therapeutics Market Attractiveness Analysis
13.16.1. By Drugs Type
13.16.2. By Application
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America Hospital Infection Therapeutics Market Analysis
14.1. Key Findings
14.2. South America Hospital Infection Therapeutics Market Overview
14.3. South America Hospital Infection Therapeutics Market Value Share Analysis, by Drugs Type
14.4. South America Hospital Infection Therapeutics Market Forecast, by Drugs Type
14.4.1. Antibiotics Drugs
14.4.2. Antifungal Drugs
14.4.3. Antiviral Drugs
14.5. South America Hospital Infection Therapeutics Market Value Share Analysis, by Application
14.6. South America Hospital Infection Therapeutics Market Forecast, by Application
14.6.1. Bloodstream Infections
14.6.2. Pneumonia
14.6.3. Surgical Site Infections
14.6.4. Urinary Tract Infections
14.6.5. Gastrointestinal Disorders
14.6.6. Other Hospital Infections
14.7. South America Hospital Infection Therapeutics Market Value Share Analysis, by Country
14.8. South America Hospital Infection Therapeutics Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil Hospital Infection Therapeutics Market Forecast, by Drugs Type
14.9.1. Antibiotics Drugs
14.9.2. Antifungal Drugs
14.9.3. Antiviral Drugs
14.10. Brazil Hospital Infection Therapeutics Market Forecast, by Application
14.10.1. Bloodstream Infections
14.10.2. Pneumonia
14.10.3. Surgical Site Infections
14.10.4. Urinary Tract Infections
14.10.5. Gastrointestinal Disorders
14.10.6. Other Hospital Infections
14.11. Mexico Hospital Infection Therapeutics Market Forecast, by Drugs Type
14.11.1. Antibiotics Drugs
14.11.2. Antifungal Drugs
14.11.3. Antiviral Drugs
14.12. Mexico Hospital Infection Therapeutics Market Forecast, by Application
14.12.1. Bloodstream Infections
14.12.2. Pneumonia
14.12.3. Surgical Site Infections
14.12.4. Urinary Tract Infections
14.12.5. Gastrointestinal Disorders
14.12.6. Other Hospital Infections
14.13. Rest of South America Hospital Infection Therapeutics Market Forecast, by Drugs Type
14.13.1. Antibiotics Drugs
14.13.2. Antifungal Drugs
14.13.3. Antiviral Drugs
14.14. Rest of South America Hospital Infection Therapeutics Market Forecast, by Application
14.14.1. Bloodstream Infections
14.14.2. Pneumonia
14.14.3. Surgical Site Infections
14.14.4. Urinary Tract Infections
14.14.5. Gastrointestinal Disorders
14.14.6. Other Hospital Infections
14.15. South America Hospital Infection Therapeutics Market Attractiveness Analysis
14.15.1. By Drugs Type
14.15.2. By Application
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. Merck & Co., Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Pfizer, Inc.
15.3.3. GlaxoSmithKline plc
15.3.4. AstraZeneca
15.3.5. Johnson & Johnson Services, Inc.
15.3.6. F. Hoffmann-La Roche Ltd.
15.3.7. Bayer AG
15.3.8. Allergan plc
15.3.9. Sanofi S.A.
15.3.10. Gilead Sciences, Inc.
15.3.11. Basilea Pharmaceutica Ltd.
15.3.12. Bristol-Myers Squibb Company
15.3.13. Actavis plc
15.3.14. Cubist Pharmaceuticals, Inc.
15.3.15. Spero Therapeutics
15.3.16. BioSpace, Inc.
15.3.17. POLYPID
15.3.18. Novartis AG
15.3.19. AbbVie Inc.
15.3.20. Bellerophon Therapeutics.

16. Primary Key Insights
  • INQUIRE BEFORE BUYING